WeVote
Log In

Bill

Bill

HB 2871

appropriation; ibogaine; clinical research study

57th Legislature - First Regular Session Introduced by Justin Wilmeth

Arizona HB 2871 appropriates state funds to conduct clinical research on ibogaine for treating opioid addiction and other conditions.

DP
0
WeVote Research Nonpartisan
Bill Summary · HB 2871

Legislative bill overview

HB 2871 appropriates state funding for a clinical research study on ibogaine, a naturally-occurring alkaloid with psychoactive properties that has shown potential in treating opioid addiction and other conditions. The bill allocates resources to conduct controlled scientific research on ibogaine's therapeutic applications within Arizona.

Why is this important

Ibogaine has demonstrated promise in addiction treatment but remains a Schedule I controlled substance federally, limiting research opportunities. Funding state-level research could generate evidence for potential medical applications while addressing Arizona's opioid crisis, and may position the state as a leader in emerging psychopharmacological research.

Potential points of contention

  • Federal-state conflict: Ibogaine's Schedule I status creates legal complications for state-funded research, requiring navigation of federal Drug Enforcement Administration regulations and potential conflicts with federal law
  • Research safety concerns: Ibogaine carries documented cardiovascular risks and potential for serious adverse effects; funding must ensure rigorous safety protocols and ethical oversight
  • Unproven efficacy: While preliminary data exists, ibogaine lacks FDA approval; concerns may exist about allocating public funds to research on compounds without established clinical benefit
  • Budget priorities: Debate over whether state resources should fund this emerging treatment versus established addiction interventions with proven outcomes

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.